Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Travis Perkins profits tank on weak sales, impairment charges

(Sharecast News) - Shares in Travis Perkins dropped sharply on Tuesday after the building materials group said it barely broke even in 2024 on the back of falling volumes and prices and an underperforming merchanting business, with the bottom line weighed down further by £139m in impairment charges. Travis Perkins, which saw its chief executive Peter Redfern step down last month due to ill health, reported revenues fell 4.7% at £4.61bn in 2024, due to a weak performance in the merchanting division, which accounts for more than 80% of the overall business.

Merchanting sales were 6.2% lower at £3.79bn as a result of price deflation and declining volumes, arising from the "depressed levels of UK construction activity and an intensely competitive backdrop", the company said.

Adjusted operating profits were down 23.2% at £152m. However, when excluding adjusting items - which included impairments in certain merchanting branches and restructuring actions, as well as write-downs in its stairs, floors and doors company Staircraft - operating profits totalled just £2m, down from £161m in 2023.

"If there was any doubt about the size of the task involved in fixing Travis Perkins then it will have vanished in the wake of an ugly set of results from the builders' merchant," said Russ Mould, investment director at AJ Bell.

Looking ahead, Travis Perkins chair Pete Redfern said that, with more resources re-deployed into customer-facing roles, the company was now "better placed to benefit from returning demand" in the UK construction market - whenever that recovery happens.

"This will be supported by disciplined capital allocation, focused on upgrading and protecting our core competitive advantages, and a clear customer-focused strategy owned by the leaders of the business. I am confident that this approach will provide attractive returns for shareholders over the medium-term."

The company paid a final dividend of 9p, up from 5.5p the year before, though the full-year payout of 14.5p was still 19.4% lower than 2023.

Shares were down nearly 7% at 512.5p by 1100 GMT, hitting their lowest since 2009.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.